All In Biotech

Drug Trial Radar · NCT04479449

Efficacy and Safety of SP-8203 in Patients With Ischemic Stroke Requiring rtPA

A Prospective, Randomized, Double-blind Phase 2b Clinical Trial to Investigate the Efficacy and Safety of SP-8203 in Patients With Acute Ischemic Stroke Requiring Recombinant Tissue Plasminogen Activator (rtPA) Standard of Care

Last checked: Nov 20, 2026Latest source record: Mar 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 178 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

178

Actual

Start

Mar 18, 2019

Primary completion

Oct 19, 2020

Study completion Dec 18, 2020

Sponsor

Sponsor type
Industry
First posted
Jul 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 19 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is designed to evaluate the efficacy and safety of the combination therapy of SP-8203 (Otaplimastat) and recombinant tissue Plasminogen Activator (rtPA) standard of care. In this clinical trial, rtPA will be injected intravenously using an infusion device. If reperfusion is not occur in spite of rtPA therapy, endovascular therapy can be performed.

Conditions

  • Ischemic Stroke

Interventions

  • SP-8203Drug

    SP-8203 80 mg will be intravenously administered as 40 mg/dose twice daily (intervals of 12 hours)

  • PlaceboDrug

    Placebo will be intravenously administered twice daily (intervals of 12 hours)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The neurological improvement evaluated by the National Institute of Health Stroke Scale (NIHSS)Time frame: Change from 0 day at 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Asan Medical Center

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.